Advertisement

Ads Placeholder
Loading...

Oryzon Genomics S.A.

ORYZF•PNK
Healthcare
Biotechnology
$3.34
$0.00(0.00%)
U.S. Market opens in 5h 11m

Oryzon Genomics S.A. (ORYZF) Stock Overview

Explore Oryzon Genomics S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap258.9M
P/E Ratio-80.77
EPS (TTM)$-0.04
ROE-0.03%
Fundamental Analysis

AI Price Forecasts

1 Month$3.37
3 Months$4.49
1 Year Target$4.58

ORYZF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Oryzon Genomics S.A. (ORYZF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 48.84, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $4.58.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -80.77 and a market capitalization of 258.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
2.77%
3-Month Change
-0.60%
6-Month Change
-7.48%
Year-to-Date (YTD) Change
-0.60%
1-Year Change
7.74%
3-Year Change
36.33%
5-Year Change
-19.52%
All-Time (Max) Change
-7.22%

Contact Information

https://www.oryzon.com
34 93 515 13 13
Sant Ferran 74, Cornellà de Llobregat, NaN, 08940

Company Facts

470 Employees
IPO DateDec 15, 2020
CountryES
Actively Trading

Frequently Asked Questions